Radioembolization for hepatocellular carcinoma using TheraSphere® | Zendy

SafiyyaMohamed Ali | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Radioembolization for hepatocellular carcinoma using TheraSphere^®

Author(s) -

SafiyyaMohamed Ali

Publication year - 2011

Publication title -

saudi journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.608

H-Index - 32

eISSN - 1998-4049

pISSN - 1319-3767

DOI - 10.4103/1319-3767.80388

Subject(s) - medicine , hepatocellular carcinoma , portal vein thrombosis , randomized controlled trial , brachytherapy , selective internal radiation therapy , radiology , radiation therapy , oncology , malignancy , microsphere , clinical trial , carcinoma , portal vein , chemical engineering , engineering

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. Radioembolization with yttrium-90 (Y90) microspheres is a new concept in radiation therapy for HCC. This review focuses on the indications, efficacy, side effects, and future direction of Y90 therapy, using TheraSphere® , in HCC patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research